Use of placental mesenchymal stem cell exosomes in the preparation of a drug for treating pulmonary fibrosis
By identifying placental mesenchymal stem cell-derived exosomes through particle size distribution, surface markers, and specific miRNA combinations, the problems of molecular-level identification and quality control in the development of pulmonary fibrosis drugs have been solved, achieving clear product definition and therapeutic efficacy.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- THE FIRST AFFILIATED HOSPITAL ZHEJIANG UNIV COLLEGE OF MEDICINE
- Filing Date
- 2026-05-27
- Publication Date
- 2026-07-17
AI Technical Summary
In the current technology, the molecular-level identification and product definition of placental mesenchymal stem cell-derived exosomes in the development of pulmonary fibrosis drugs are not clear enough, making it difficult to achieve product consistency and quality control.
We provide placental mesenchymal stem cell-derived exosomes, which are identified at the molecular level through particle size distribution, surface marker expression, and specific miRNA combinations, and can be used to treat pulmonary fibrosis by combining them with intratracheal administration.
This study achieved clear source characteristics and molecular cargo fingerprinting of exosomes, improving product identification and quality control, significantly improving lung tissue pathological damage, and reducing fibrosis-related molecular indicators.
Smart Images
Figure CN122398858A_ABST